| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/03/2012 | CA2490200C 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
| 01/03/2012 | CA2486712C Method of treating diabetes |
| 01/03/2012 | CA2484184C Minoxidil foam formulation |
| 01/03/2012 | CA2484100C Novel biomaterials, their preparation and use |
| 01/03/2012 | CA2466054C Apo-2 ligand/trail formulations |
| 01/03/2012 | CA2463134C Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| 01/03/2012 | CA2453243C Treatment of nail infections with no |
| 01/03/2012 | CA2446837C Stable high-concentration injection containing pyrazolone derivative |
| 01/03/2012 | CA2428728C Combination antiperspirant and antimicrobial compositions |
| 01/03/2012 | CA2399505C Nasal calcitonin formulations |
| 01/03/2012 | CA2399293C Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| 01/03/2012 | CA2395684C Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 01/03/2012 | CA2374356C Granules containing a plant substance and method for producing the same |
| 01/03/2012 | CA2331257C Use of tetracyclines for treating meibomian gland disease |
| 01/03/2012 | CA2284000C Hydrophilic binary systems for the administration of cyclosporine |
| 01/03/2012 | CA2264562C Sustained peptide-release formulation |
| 01/03/2012 | CA2222889C Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| 12/29/2011 | WO2011163669A2 Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones |
| 12/29/2011 | WO2011163614A2 Methods of treatment for esophageal inflammation |
| 12/29/2011 | WO2011163600A2 Tacrolimus compositions for aerosol administration |
| 12/29/2011 | WO2011163321A2 Composition and method of treating lipid encapsulated virus infections |
| 12/29/2011 | WO2011163206A2 Controlled release compositions with reduced food effect |
| 12/29/2011 | WO2011163136A2 Tuned multifunctional magnetic nanoparticles for biomedicine |
| 12/29/2011 | WO2011163090A1 Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| 12/29/2011 | WO2011162951A1 Compositions and methods for enhancing reduction of spore-forming microorganism |
| 12/29/2011 | WO2011162944A1 Stabilized chemical composition |
| 12/29/2011 | WO2011162818A2 Lecithin carrier vesicles and methods of making the same |
| 12/29/2011 | WO2011162756A1 Therapeutic oral composition |
| 12/29/2011 | WO2011162752A1 Topical ophthalmic suspensions containing tobramycin and dexamethasone |
| 12/29/2011 | WO2011162560A2 Pharmaceutical composition in which solubility of partially soluble tricyclic derivative is improved |
| 12/29/2011 | WO2011162421A2 Foam-type external skin preparation |
| 12/29/2011 | WO2011162413A1 Sustained-release formulation |
| 12/29/2011 | WO2011162300A1 Crystal of fused pyridine compound salt |
| 12/29/2011 | WO2011162094A1 Process for producing emulsifier-producing material, process for producing emulsifier, emulsifier for orally administered composition, and orally administered composition |
| 12/29/2011 | WO2011161689A1 Imatinib mesilate pharmaceutical tablet |
| 12/29/2011 | WO2011161666A2 Enclosed liquid capsules |
| 12/29/2011 | WO2011161658A1 Ingredient delivery system |
| 12/29/2011 | WO2011161618A1 Stable formaldehyde-free microcapsules |
| 12/29/2011 | WO2011161531A1 Pharmaceutical composition containing goserelin for in-situ implant |
| 12/29/2011 | WO2011161504A1 Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof |
| 12/29/2011 | WO2011161501A2 Solid compositions in form of powders or granulates for the oral administration of active ingredients and method for obtaining them |
| 12/29/2011 | WO2011161439A1 Pharmaceutical composition comprising midazolam |
| 12/29/2011 | WO2011161263A1 Pharmaceutical compositions for cutaneous administration |
| 12/29/2011 | WO2011161236A1 Stabilized active compound |
| 12/29/2011 | WO2011161223A2 Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts |
| 12/29/2011 | WO2011161220A1 Hyperosmotic preparations comprising 5 -amino levulinic acid or derivative as photosensitizing agent |
| 12/29/2011 | WO2011161209A1 Injectable formulation of a macrocyclic lactone and levamisole |
| 12/29/2011 | WO2011161165A1 Long-term storage of non-glycosylated recombinant human g-csf |
| 12/29/2011 | WO2011161056A2 Dialysis precursor composition |
| 12/29/2011 | WO2011161055A1 Dialysis precursor composition |
| 12/29/2011 | WO2011160920A1 Dry powder formulation comprising an antimuscarinic drug |
| 12/29/2011 | WO2011160849A1 Taste-masked pharmaceutical formulation having accelerated onset of action |
| 12/29/2011 | WO2011160840A1 Method of producing pharmacologically pure crystals |
| 12/29/2011 | WO2011160839A1 Neramexane multiple unit dosage form |
| 12/29/2011 | WO2011160798A1 Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof |
| 12/29/2011 | WO2011160541A1 Tolvaptan solid dispersion and its preparation method |
| 12/29/2011 | WO2011160437A1 Plaster applied to tiantu acupoint of anterior neck fossa for treating common cold and nasal obstruction |
| 12/29/2011 | WO2011160434A1 Preparing process and quality controlling method for an compound injection |
| 12/29/2011 | WO2011160425A1 Preparing method of allicin injection and low temperature continuous stirring ultrafiltration device thereof |
| 12/29/2011 | WO2011160184A1 Method of treatment |
| 12/29/2011 | WO2011160145A1 Use of cellulose in tablets |
| 12/29/2011 | WO2011139594A3 Artificial bursa for intra-articular drug delivery |
| 12/29/2011 | WO2011139414A3 Dexlansoprazole polymorphic forms |
| 12/29/2011 | WO2011136751A3 Water soluble pharmaceutical composition |
| 12/29/2011 | WO2011135581A8 Pharmaceutical compositions of dronedarone |
| 12/29/2011 | WO2011131943A3 Pharmaceutical compositions |
| 12/29/2011 | WO2011127629A9 Pharmaceutical product of diphosphonate injection and preparation method thereof |
| 12/29/2011 | WO2011127456A3 Method for formulating large diameter synthetic membrane vesicles |
| 12/29/2011 | WO2011124667A3 Process for the preparation of essentially spherical lyophilisates |
| 12/29/2011 | WO2011122934A3 Bioencapsule and method thereof |
| 12/29/2011 | WO2011109367A3 Methods and compositions for treating or preventing symptoms of hormonal variations |
| 12/29/2011 | WO2011101831A3 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - clobetasone butyrate, and an antifungal agent -terbinafine hydrochloride and a process to make it |
| 12/29/2011 | WO2011101829A3 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - betamethasone dipropionate and an antifungal agent - miconazole nitrate, and a process to make it |
| 12/29/2011 | WO2011101827A3 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - clobetasone butyrate, and an antifungal agent - miconazole nitrate, and a process to make it |
| 12/29/2011 | WO2011101822A3 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, and a corticosteroid - dexamethasone acetate, and a process to make it |
| 12/29/2011 | WO2011100376A3 Methods and architecture for power optimization of iontophoretic transdermal drug delivery |
| 12/29/2011 | WO2011098285A8 Dermatological, pharmaceutical composition suitable for oligonucleotides |
| 12/29/2011 | WO2011097081A3 Methods and compositions for oxygenation of skin to treat skin disorders |
| 12/29/2011 | WO2011090349A3 Nanocarrier having enhanced skin permeability, cellular uptake and tumour delivery properties |
| 12/29/2011 | WO2011083112A3 Solid oral dosage form containing olmesartan medoxomil |
| 12/29/2011 | WO2011082141A3 Ingestible tablet dispensers and methods of dispensing tablets |
| 12/29/2011 | WO2011048491A3 Amorphous rotigotine co-precipitates |
| 12/29/2011 | WO2011039675A3 Latrepirdine transdermal therapeutic dosage forms |
| 12/29/2011 | WO2011035013A3 Implant devices that differ by release profile and methods of making and using same |
| 12/29/2011 | WO2011022199A3 Multi-layer transdermal patch |
| 12/29/2011 | WO2011013032A3 Method for the preparation of microparticles with efficient bioactive molecule incorporation |
| 12/29/2011 | WO2011007327A3 Suspension for therapeutic use and device for delivering said suspension |
| 12/29/2011 | WO2011006596A3 Aqueous solution and gelatinized composition comprising a phosphodiesterase-5 inhibitor and corresponding methods and use |
| 12/29/2011 | WO2010151746A3 Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure |
| 12/29/2011 | WO2010142284A3 Arrangement for the remote-controlled release of active substances |
| 12/29/2011 | WO2010132882A8 Sublingual dexmedetomidine compositions and methods of use thereof |
| 12/29/2011 | WO2001035902A3 Stabilized thyroxine compounds |
| 12/29/2011 | US20110321200 Rejuvenation or preservation of germ cells |
| 12/29/2011 | US20110319503 Soft capsule based on starch and a method and device for the production thereof |
| 12/29/2011 | US20110319486 Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same |
| 12/29/2011 | US20110319457 Deferacirox dispersible tablets |
| 12/29/2011 | US20110319395 Pharmaceutical Formulation of Olanzapine |
| 12/29/2011 | US20110319368 Once daily formulations of tetracyclines |
| 12/29/2011 | US20110318423 Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content |
| 12/29/2011 | US20110318422 Targeted active agent delivery system based on calcium phosphate nanoparticles |